March 21st 2024
Last week, BMS announced that the FDA Oncologic Drugs Advisory Committee (ODAC) has voted in favor of BMS’s and 2seventy bio's Abecma (idecabtagene vicleucel) for patients with relapsed or refractory multiple myeloma in earlier lines of therapy.
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More